🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: Glycopyrronium

Found 200 matching trials

Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD

PHASE2

The overall objective of this study was to assess the efficacy and safety o...

Status

Completed

Location

Pearl Investigative Site

Start Date

2015-01-28

Trial ID

NCT03256552

Treatments Being Tested

Glycopyrronium MDI 28.8 micrograms Glycopyrronium MDI 14.4 micrograms Glycopyrronium MDI 7.2 micrograms Placebo MDI

Non-inferiority Evaluation of Trimbow in Critically Ill Patients Admitted in ICU Compared to Standard of Care

PHASE4

Objective: To evaluate non-inferiority of Trimbow, an approved therapy for ...

Status

Unknown

Location

Multiple Locations

Start Date

2021-02-15

Trial ID

NCT04737655

Treatments Being Tested

TRIMBOW® pressurised inhalation solution: Beclometasone dipropionate / formoterol fumarate /glycopyrronium 87/5/9 µg per inhalation

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

This study was designed to investigate the 1 year efficacy and safety of th...

Status

Completed

Location

Novartis Investigative Site

Start Date

2009-06

Trial ID

NCT00929110

Treatments Being Tested

Glycopyrronium bromide Placebo to glycopyrronium bromide Tiotropium

EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)

N/A

A retrospective real-world data study, assessing the relationship between t...

Status

Completed

Location

AstraZeneca

Start Date

2024-08-15

Trial ID

NCT07103642

Treatments Being Tested

BGF

A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) With a Next-generation Propellant (NGP) With a Spacer, BGF MDI Hydrofluoroalkane (HFA) With a Spacer, as Well as BGF MDI NGP Without a Spacer

PHASE1

The primary purpose of this study is to demonstrate the equivalence of bude...

Status

Withdrawn

Location

Multiple Locations

Start Date

2024-10-17

Trial ID

NCT06340581

Treatments Being Tested

Treatment A: BGF MDI HFA Treatment B: BGF MDI HFO Treatment C: BGF MDI HFO AeroChamber Plus Flow-Vu Spacer

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

PHASE3

The purpose of the study is to provide long term safety data of NVA237. Thi...

Status

Completed

Location

Novartis Investigative Site

Start Date

2012-10

Trial ID

NCT01697696

Treatments Being Tested

NVA237 Long-acting beta 2-agonist (LABA)Placebo

Efficacy of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) (CHF 5993)Administered Via Dry Powder Inhaler (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

The purpose of this study is to evaluate the efficacy of Fixed Combination ...

Status

Completed

Location

Medical Center Convex EOOD

Start Date

2018-06-15

Trial ID

NCT03590379

Treatments Being Tested

CHF 5993 DPI CHF5993 pMDI CHF 1535 pMDI Placebo DPI Placebo pMDI

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

PHASE3

This is a variable length study to evaluate the efficacy and safety of bude...

Status

Completed

Location

Research Site

Start Date

2021-03-01

Trial ID

NCT04609904

Treatments Being Tested

BGF MDI 320/28.8/9.6 μg BGF MDI 320/14.4/9.6 μg BFF MDI 320/9.6 μg BFF pMDI 320/9 μg

Comparative Effects of Triple Inhaled Therapy With Budesonide/Glycopyrronium/Formoterol Versus Fluticasone Furoate/Umeclidinium/Vilanterol on Small Airway Disease in COPD Patients: A Randomized Crossover Study

PHASE4

The goal of this clinical trial is to determine if triple inhaled therapy w...

Status

Completed

Location

Narongkorn Saiphoklang

Start Date

2025-04-01

Trial ID

NCT06905483

Treatments Being Tested

Budesonide/Glycopyrronium/Formoterol (BGF)Fluticasone Furoate/Umeclidinium/Vilanterol (FUV)

Assessment of Safety, Tolerability and Efficacy of 1% GPB Cream Versus Qbrexza® (Glycopyrronium) Cloth 2.4% Under Maximum-Use Conditions in Subjects with Primary Axillary Hyperhidrosis

PHASE2

The aim of this study is to investigate the safety, tolerability and effica...

Status

Withdrawn

Location

Multiple Locations

Start Date

2019-12

Trial ID

NCT04159610

Treatments Being Tested

WO3970 Qbrexza® (glycopyrronium) cloth, 2.4%, for topical use

Previous Next